# A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

> **NCT05514717** · PHASE1 · RECRUITING · sponsor: **Mersana Therapeutics** · enrollment: 162 (estimated)

## Conditions studied

- HER2-positive Breast Cancer
- HER2-positive Gastric Cancer
- HER2-positive Non-Small Cell Lung Cancer
- HER2-positive Colorectal Cancer
- HER2-positive Tumors
- HER2 Low Breast Cancer

## Interventions

- **DRUG:** XMT-2056

## Key facts

- **NCT ID:** NCT05514717
- **Lead sponsor:** Mersana Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-24
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 162 (ESTIMATED)
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05514717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05514717, "A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05514717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*